Company / Cash & Equivalents
P3 Health Partners Inc. Cash & Equivalents History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$25.0M
FY2024
5-year range
$5.3M / $36.3M
FY2021-FY2024
Trend
-31.1%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $5M to $25M over the past 2 years.
Based on SEC 10-K filings.
$25M in FY2024 with a 3-year CAGR of -11.6%.
Improved from $5M to $25M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -11.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -11.6%, indicating a declining trend.
- In FY2024, cash & equivalents decreased 31.1% year-over-year.
Company context
Key Data Points
- Altman Z-Score 0.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $25.0M | -31.1% |
| FY2023 | $36.3M | +585.2% |
| FY2022 | $5.3M | -85.4% |
| FY2021 | $36.3M | - |
As of FY2024 · SEC 10-K · Updated Jun 28, 2026